RT Journal Article
SR Electronic
T1 Safe in my heart: resting heart rate variability longitudinally predicts emotion regulation, worry and sense of safeness during COVID-19 lockdown
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21259071
DO 10.1101/2021.06.17.21259071
A1 Elena Makovac
A1 Luca Carnevali
A1 Sonia Hernandez-Medina
A1 Andrea Sgoifo
A1 Nicola Petrocchi
A1 Cristina Ottaviani
YR 2021
UL http://medrxiv.org/content/early/2021/06/23/2021.06.17.21259071.abstract
AB Due to its ability to reflect the capacity to engage in context-appropriate responses, tonic heart rate variability (HRV) is considered a putative biomarker of stress resilience. However, most studies are cross-sectional, precluding causal inferences. The high levels of uncertainty and fear at a global level that characterize the COVID-19 pandemic offer a unique opportunity to investigate the longitudinal role of HRV in stress resilience. The present study examined whether HRV, measured about 2 years earlier (Time 0), could predict emotion regulation strategies and daily affect in healthy adults during the May 2020 lockdown (Time 1). Moreover, we evaluated the association between HRV measures, emotion regulation strategies, subjective perception of COVID-19 risk, and self-reported depressive symptoms at Time 1. Higher tonic HRV at Time 0 resulted a significant predictor of a stronger engagement in more functional emotion regulation strategies, as well as of higher daily feelings of safeness and reduced daily worry at Time 1. Moreover, depressive symptoms negatively correlated with HRV and positively correlated with the subjective perception of COVID-19 risk at Time 1. Current data support the view that HRV might be not only a marker but also a precursor of resilience under stressful times.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs of Kings College London LRS-19/20-18429:COVID-19 and Sapienza University of Rome Prot. 0000653 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request to the authors.